Golden State Wealth Management LLC Takes $79,000 Position in Natera, Inc. (NASDAQ:NTRA)

Golden State Wealth Management LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 500 shares of the medical research company’s stock, valued at approximately $79,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Natera by 10.3% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 740,837 shares of the medical research company’s stock worth $117,274,000 after purchasing an additional 69,455 shares during the period. Silver Oak Securities Incorporated increased its holdings in Natera by 3.1% during the fourth quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company’s stock worth $470,000 after buying an additional 89 shares during the last quarter. Choreo LLC raised its position in Natera by 12.5% in the fourth quarter. Choreo LLC now owns 1,986 shares of the medical research company’s stock worth $315,000 after acquiring an additional 220 shares during the period. Yousif Capital Management LLC purchased a new position in Natera in the fourth quarter valued at about $207,000. Finally, GDS Wealth Management grew its position in shares of Natera by 245.0% during the 4th quarter. GDS Wealth Management now owns 12,463 shares of the medical research company’s stock valued at $1,973,000 after acquiring an additional 8,851 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Buying and Selling at Natera

In other news, CEO Steven Leonard Chapman sold 4,728 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $146.41, for a total value of $692,226.48. Following the transaction, the chief executive officer now directly owns 185,034 shares in the company, valued at $27,090,827.94. The trade was a 2.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gail Boxer Marcus sold 2,212 shares of the stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $158.53, for a total value of $350,668.36. Following the completion of the sale, the director now owns 19,386 shares in the company, valued at approximately $3,073,262.58. The trade was a 10.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 312,394 shares of company stock valued at $52,333,520 in the last quarter. Company insiders own 7.60% of the company’s stock.

Natera Trading Down 1.3 %

NASDAQ NTRA opened at $172.82 on Monday. The stock has a 50-day moving average of $167.66 and a 200-day moving average of $140.97. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 1-year low of $67.33 and a 1-year high of $183.00. The firm has a market cap of $22.82 billion, a PE ratio of -98.19 and a beta of 1.66.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. During the same quarter in the previous year, the company posted ($0.95) earnings per share. The business’s revenue was up 63.9% on a year-over-year basis. As a group, sell-side analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Ratings Changes

NTRA has been the topic of a number of research reports. TD Cowen lifted their price target on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Robert W. Baird boosted their target price on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. increased their price target on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Finally, Craig Hallum upped their price objective on shares of Natera from $121.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $165.88.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.